Tags : Type-2 diabetes

Clinical Trials

Lilly Presents the Results of Tirzepatide in SURPASS-1 Trial for

Shots: The SURPASS-1 study involves assessing the efficacy & safety of Tirzepatide as monothx. (5/10/15 mg) vs PBO in 478 patients in the ratio (1:1:1:1) with T2D inadequately controlled with diet & exercise alone across US, Mexico, India & Japan Results: A1C reduction: (-1.87% /-1.89%/-2.07% vs +0.04%); Weight reduction: (-7.0/-7.8/-9.5kg vs-0.7 kg); percentage of participants […]Read More

Clinical Trials

Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for

Shots: The P-III SURPASS-2 trial involves assessing Tirzepatide (5/10/15mg) vs Semaglutide (1mg) in 1,879 patients in a ratio (1:1:1:1) with T2D inadequately controlled with ≥1500 mg/day metformin alone for 40wks. Results: A1C reduction: (-2.09% /-2.37%/-2.46% vs- 1.86%); Weight reduction: (-7.8/-10.3/-12.4kg vs -6.2 kg); patients achieving A1C <7% (5.5%/88.9%/ 92.2% vs 81.1%); patients achieving A1C <5.7% […]Read More

Clinical Trials

Lilly Reports Results of Tirzepatide in P-lll SURPASS-1 Monotherapy Trial

Shots: The P-lll SURPASS-1 study involves assessing Tirzepatide as monothx. (5/10/15 mg) vs PBO in 478 patients in the ratio of (1:1:1:1) with T2D inadequately controlled with diet and exercise alone Results: A1C reduction: (-1.75% /-1.71%/-1.69% vs- 0.09%); Weight reduction: 6.3/7.0/7.8kg vs 1.0 kg; percentage of participants achieving A1C <7%: 81.8%/84.5%/ 78.3% vs 23.0%; percentage […]Read More

Regulatory

Eli Lilly and Boehringer Ingelheim’s Triple Regimen Receive the US

Shots: The US FDA has approved Trijardy XR which includes Jardiance (empagliflozin), Tradjenta (linagliptin) and metformin hydrochloride extended-release to lower blood sugar in adults with T2D, along with diet and exercise The approval is based on Trijardy XR assessing the bioequivalence of Trijardy XR and their individual components in healthy adults, demonstrating a consistent safety […]Read More

Pharma

Novo Nordisk Signs a Five-Year Agreement with UVA Center for

Shots: UVA in collaboration with Novo Nordisk to co-develop virtual patient modeling for T2D patients. The collaboration will utilize UVA’s work and insights on patient simulation and data-driven models within diabetes and will initially have 15 employees with an expectation of increment The focus of the collaboration is developing ‘virtual innovation lab’ for gaining deep […]Read More